Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2233522 | 0.79 | NPC1 (0.69) | NPC1ALDH1A1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL589813 | 0.78 | NPC1 (0.85) | NPC1ALDH1A1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL5055502 | 0.77 | NPC1 (0.58) | NPC1ALDH1A1RAB9ANAAAMGLL | |
| SCHEMBL22497489 | 0.76 | KDM4E (0.61) | NPC1ALDH1A1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL8541015 | 0.75 | PPARG (0.51) | NPC1ALDH1A1RAB9ATSHRCYP3A4 | |
| SCHEMBL22497553 | 0.75 | RAB9A (0.52) | NPC1ALDH1A1RAB9AKDM4EMEN1 | |
| SCHEMBL14441238 | 0.74 | HCAR2 (0.62) | NPC1ALDH1A1RAB9ATSHRKDM4E | |
| SCHEMBL18101229 | 0.74 | CYP3A4 (0.52) | NPC1ALDH1A1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL18101287 | 0.74 | CYP3A4 (0.52) | NPC1ALDH1A1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL18101227 | 0.74 | CYP3A4 (0.52) | NPC1ALDH1A1RAB9AMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139565-A1 | Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia | SMITHKLINE BEECHAM CORPORATION | 2008-06-12 | — | — | US | claimed |
| US-20080139565-A1 | Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia | SMITHKLINE BEECHAM CORPORATION | 2008-06-12 | — | — | US | disclosed |
| US-20080139565-A1 | Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia | SMITHKLINE BEECHAM CORPORATION | 2008-06-12 | — | — | US | disclosed |
| US-20080139565-A1 | Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia | SMITHKLINE BEECHAM CORPORATION | 2008-06-12 | — | — | US | disclosed |
| EP-1848707-A1 | AWTHRANILIC ACID DERIVATIVES AND THEIR USE IN TREATMENT OF DISEASES OF LIPID METABOLISM, IN PARTICULAR DYSLIPIDAEMIA | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006085108-A1 | AWTHRANILIC ACID DERIVATIVES AND THEIR USE IN TREATMENT OF DISEASES OF LIPID METABOLISM, IN PARTICULAR DYSLIPIDAEMIA | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139565-A1 | Anthranilic Acid Derivatives and Their Use in Treatment of Diseases of Lipid Metabolism, in Particular Dyslipidaemia | ANTXR2, CYP46A1, HCAR1 | NPC1 961/4885ALDH1A1 1540/4885RAB9A 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.